IRCT20100520003979N9 IRCT 2018-10-19 Ahvaz University of Medical Sciences Evaluation the effect of atypical antipsychotic augmentation with Atomoxetine The evaluation of atypical antipsychotic augmentation with Atomoxetine in the reduction of negative symptoms in patients with Schizophrenia 2018-10-23 anticipated 60 Complete https://irct.ir/trial/34090 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on the method of the permutation blocks of size 4, individuals are randomly divided into two groups, Blinding description: The placebo is similar to atmoxtein in shape, color, smell and taste and will be available at the Faculty of Pharmacy, Ahwaz University of Medical Sciences. The medication will be prescribed by the assistants and given to the patients by the nurses at psychiatric ward. The project executor is not aware of the prescriptions in each group. Also, the patient is not aware of the type of medicine takes. 2-3 Schizophrenia. Intervention 1: Intervention group: Atomoxetine is given 40 mg daily in the first week and 80 mg daily in the following weeks until 8 weeks. The effect of the medication on the negative symptoms in the two groups is compared with the PANSS scale at the start of the treatment and the weeks 4th and 8th for negative signs and the overall score scales. Intervention 2: Control group: This group will receive placebo which is similar to Atomoxtein in shape, color, smell, and taste. No - There is not a plan to make this available Justification or reason for not sharing IPD is No more information